Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Abaloparatide cycle length: what human studies ran

FDA-approvedAHuman trial evidence
Short answer: Abaloparatide has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Abaloparatide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Abaloparatide cycle length?
No cycle is defined. Abaloparatide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Abaloparatide?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Abaloparatide dosing reference Full research page

References

  1. TYMLOS (abaloparatide) injection, for subcutaneous use, prescribing information (DailyMed, effective 08/2026) FDA label (DailyMed). 2026
  2. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial (ACTIVE) JAMA. 2016
  3. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial (ATOM) J Bone Miner Res. 2022
  4. Drugs@FDA (openFDA) application record NDA 208743, TYMLOS U.S. FDA. 2026
  5. World Anti-Doping Agency Prohibited List 2026 (online version) WADA. 2026
  6. PubChem compound record for abaloparatide PubChem. 2026